A complete reference for every major GLP-1 medication — semaglutide, tirzepatide, liraglutide, and more. Each drug page covers FDA-approved uses, mechanism of action, dosing schedules, efficacy data from clinical trials (with actual percentages and source citations), side effects with incidence rates, cost, and access options.
Drug Profiles
- Semaglutide — the molecule behind Ozempic, Wegovy, and Rybelsus
- Wegovy — semaglutide 2.4mg, FDA-approved for weight management
- Ozempic — semaglutide for type 2 diabetes, widely used off-label for weight loss
- Oral Wegovy (25mg pill) — FDA-approved December 2025, launched January 2026
- Tirzepatide — the molecule behind Mounjaro and Zepbound
- Mounjaro / Zepbound — dual GIP + GLP-1 agonist
- Liraglutide (Saxenda / Victoza) — older daily-injection GLP-1
Drug Comparisons
- Ozempic vs Wegovy — same drug, different approved uses
- Semaglutide vs Tirzepatide — which produces more weight loss?
- Wegovy Injection vs Wegovy Pill — STEP vs OASIS trial data compared
- Branded vs Compounded Semaglutide — what is actually different
All drug information is sourced from FDA prescribing information, peer-reviewed clinical trials, and published pharmacology data. See our Medical Disclaimer. This is not medical advice.